Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of FCN-159 versus investigator's choice therapy in pediatric low-grade glioma with KIAA1549-BRAF fusion or BRAF V600E mutation
CTR20252088Phase 3Active
- Sponsor
- Fosun Pharma
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of luvometinib in childhood low-grade glioma (pLGG), sponsored by Fosun Pharma. Started Jun 2025; status: active.
02
Drugs
luvometinib
03
Conditions
childhood low-grade glioma (pLGG)
Beyond the preview
Go deeper on CTR20252088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252088.